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RESEARCH NEEDS IN 11 MAJOR AREAS IN DERMATOLOGY 
I. Psoriasis 
PREY ALENCE AND SEVERITY 
Psoriasis is a papulosquamous disease of the skin that pro-
duces stigmatizing chronic recurrent lesions that are often 
emotionally and physically debilitating to the patient. More-
over, treatment is expensive. Frequently, lifelong treatment is 
required. 
Commonly, the characteristic cutaneous lesions of psoriasis 
are round, erythematous dry patches of various sizes covered 
by abundant, grayish-white imbricated scabs. Although they 
have a predilection for the scalp, nails, and extensor surface of 
the limbs, the lesions may cover the entire body, producing an 
erythroderm. 
Previous estimates have indicated that there are 2 to 8 million 
persons with psoriasis in the United States. However, recent 
estimates indicate 1-3 million with psoriasis and a prevalence 
rate of 0.5-1.5%. Between 150,000-260,000 new cases of psoriasis 
occur annually. Reviews of data from the 1968 National Pro-
gram for Dermatology confIrm a prevalence rate of 1-2% of the 
population or 3-4% if milder cases of psoriasis are included. 
Population studi'es from smaller countries indicate the preva-
lence of psoriasis to be: Sweden 3%, Faroe Islands 3%, Japan 
1%. 
In 1977 a study of Manpower for Dermatologic Care spon-
sored by the American Academy of Dermatology indicated that 
psoriasis had the highest number of repeat visits per year of 
any skin disease (Table I). They estimated 1.5 million hours of 
physician time per year expended in the care of psoriasis alone, 
or 4% of the time a dermatologist spends on care of all skin 
diseases. 
Estimates of Annu.al Costs 
Table II, based on data obtained from the pharmaceutical 
industry, projects estimated retail sales of prescription drugs. 
Table III is an estimate of the annual costs for care of 
psoriasis in the United States. 
The total cost of $248 million may be a conservative fIgure 
for the care of psoriasis in the United States as there is no 
accurate way to estimate the amount of over-the-counter drugs 
purchased by patients. Over-the-counter drugs, however, must 
greatly exceed the sales of prescribed medication. 
Hospitalization costs for psoriasis in the State of Michigan, 
projected to the entire population of the 'U .S.A., indicate that 
approximately 10,000 psoriatics are hospitalized each year for 
an average of 18 days each (Table III). If the cost is $200 per 
day in the hospital, $36 million annually is required for hospi-
talization treatment of psoriasis. . 
The development of photochemotherapy, an outpatient 
treatment, offers an alternative to expensive hospitalization for 
severe psoriatics. Cooperative studies show that the same num-
ber of outpatients could be treated for a year' with photochem-
otherapy for 1/3 the cost of hospitalized patients. 
One million psoriatics make an average of 2.4 office visits to 
a dermatologist per year at an annual cost to the patient of 
about $50 per year or $50 million for physician care alone. 
Carroll and Johnson recently studied the fInancial impact of 
psoriasis in a group of 100 patients. They found that the average 
expenditure per year for direct costs (physicians fees, medica-
tions, hospitalization) and indirect costs (loss of work days) was 
$5,456, much more than anticipated. 
PREVENTION, TREATMENT, AND CURE 
Psoriasis is neither preventable nor curable at the present 
time. There are few drugs, which can be taken internally or 
applied locally to the skin, that are capable of partially or 
totally eliminating the lesions of psoriasis. All ofthese measures 
are temporary, and the disease returns soon after treatment is 
withdrawn; occasionally it persists in the face of continued 
treatment. All systemic drugs that have a measurable effect on 
the psoriatic lesions have undesirable side effects. For some 
drugs these side effects can be extremely serious and can 
occasionally result in death. There is general agreement that in 
order to justify the use of these systemic drugs, the patient 
must be suffering from a severe form of psoriasis. Local agents 
are capable of controlling the lesions to a certain extent al-
though they are not as effective as systemic agents. However, 
since many of the topical agents are relatively benign and lead 
only to minimum side effects, they are the most widely used in 
managing the disease. 
PUV A therapy, which combines an oral medication with 
local exposure of the skin to ultraviolet light, has been very 
effective in controlling the lesions of psoriasis. Immediate side 
effects are quite tolerable. There are at least two major prob-
lems in PUV A treatment: the possibility of long-term damage 
to the skin that might result in multiple malignancies of the 
skin, and the possibility that cataracts might form prematurely. 
In all probability it will take more than 10 years of exposure to 
PUV A treatment to decide whether the patient is at risk, how 
much the incidence of malignancies will increase, how severe 
these malignancies will be, and how deeply they may penetrate. 
Cutaneous malignancies from radiation dermatitis (due to x-
ray) take from 10 to 20 years to develop; the average malignancy 
after damage to the skin by ionizing radiation, 15 years. If the 
effect of PUV A treatment is analogous to this, it may take at 
least 10 years to fInd out whether PUV A treatment may induce 
malignancy in human skin . 
Topical steroids are potent enough to improve about 50% of 
psoriatic lesions; however, there are no long-term remissions. 
Even more potent steroids are being developed. Whether they 
can be used is problematical. Both the local and systemic side 
effects of the potent topical steroids we now have are strong 
enough to suggest that we have reached close to the optimum 
strength that balances effectiveness against side effects. 
Antimetabolites that do not act directly on DNA have some 
promise in the management of psoriasis, e.g., methotrexate and 
cycloheximide. Those cytotoxic agents that may directly affect 
'DNA, such as alkylating agents, are suspect, however, because 
of the ·risk of malignancy with long-term use. 
Since psoriasis frequently occurs in families, a genetic com-
ponent in many, if not all , cases may be the culprit. Therefore, 
theoretically, modification of the genotype or environment 
should lead to a decrease in the frequency of the disease. 
Genetic counseling would be feasible if adequate genetic 
markers could be identifIed. Among possible markers are HLA 
phenotypes and biochemical phenomena such as propranolol 
induced hyperproliferation of uninvolved epidermis. Environ-
mental factors, such as temperature and humidity, appear to 
alter the clinical symptoms. Identification and avoidance of 
precipitating events in susceptible patients, e.g., strep infection, 
would do much to decrease the morbidity of psoriasis. 
Major advances in treatment of psoriasis in the past 10 years 
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TABLE I. 
No. of visits required to bring disease into remission 6.14 
No. of visits per year to maintain remission (chronic) 8.82 
No. of years expected under care 11.44 
Physician time spent per visit· minutes 
Ini tial 22.48 
FoUowup 9.20 
Topical corticosteroids 
Miscellaneous dermatolog· 
ics 
Coal tar 
Anti-metabolites 
TABLE II. 
% of Patients 
Using 
68% 
22% 
16%) 
12% 
Tota l Sales 
$39.4 million 
$7.5 million 
Annual Cost 
Per Patient 
$50.90 
$9.70 
TABLE III. Total Yearly Costs 
Outpatient physician fees 
Hospitalization 
Photochemotherapy 
Derrnatologic drugs 
OTe drugs 
$50 million 
36 million 
15 million 
47 million 
100 million 
$248 million 
have dramatically reduced the morbidity of this disease. Mod-
ification and improvement of photochemotherapy and chemo-
therapy, both systemic and topical, could further reduce the 
clinical manifestations. Although the cure for psoriasis contin-
ues to elude us, new approaches to therapy have greatly dimin-
ished the symptoms of this disease. 
STATUS OF BASIC RESEARCH 
One cannot say with certainty what the initial pathological 
lesion is in psoriasis. The lack of a satisfactory animal model is 
a severe handicap in psoriasis research. There is no certain way 
to induce the lesion in humans except by initants that can 
induce a Koebner phenomenon, currently one of the best ex-
periInental approaches to the study of psoriatic lesion. However, 
no one seems to have studied the Koebner reaction carefully 
enough to identify the very early pathological changes that take 
place. Furthermore, experimental pathologic changes from the 
Koebner phenomena must be separated from the initial pso-
riatic lesion. The best guess is that the initial proliferation of 
epidermis is secondary to some unknown biochemical stimulus. 
An increase in cellular proliferation takes place which then 
leads to poor differentiation. Thus, better understanding of the 
factors that regulate growth and differentiation of epidermal 
cells is of paramount importance in elucidating the pathogenesis 
of psoriasis. 
One of the critical questions is, "What role do macrophages 
and lymphocytes play in the initial pathological lesion?" It is 
not clear if lymphocytes initiate a psoriatic lesion. Certainly 
numerous lymphocytes surround the superficial vessels of the 
derrnis in all psoriatic lesions. It could be that cellular inmtrates 
trigger the original lesion ofpsorlll-sis. Minimal experimentation 
has been done in this area. Braverman has found evidence of 
abnormal intercellular spaces in capillaries associated with pso-
riatic lesions as well as in the uninvolved psoriatic skin. It is an 
open question whether this is primary or secondary to the 
development of the psoriatic lesion. 
Epidermal Proliferation 
The epidermis is a constantly renewing cell population. Re-
newal kinetics vary with different skin abnormalities. Cell pro-
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liferation kinetics in psoriasis has been intensively investigated 
and compared to that in normal skin during the past 15 years. 
Morphologic and radioactive studies suggested that psoriatic 
epithelium proliferates more rapidly than normal epithelium. 
Autoradiographic studies showed a 7-fold increase in transit 
time of psoriatic cells. The concept of rapid cell turnover in 
psoriasis is readily supported by the clinically observed over-
production of stratum corneum that accumulates at the surface. 
Specific data has revealed that the duration of the cell cycle is 
37 hours in psoriasis and 400 hours in normal epidermis. Other 
studies have found a somewhat longer cell cycle in psoriasis but 
not enough longer to negate the most plausible of the explana-
tions: that the abnormally rapid cell cycle is responsible for the 
pathophysiologic defect in psoriasis. 
Does a Go subpopulation (resting proliferative cells) exist in 
normal epidermis? If so, it complicates interpretation of the 
above data, all of v.:-hich has been calculated on the assumption 
that the prohferatlve cells are all cycling, i.e., there is no G-J 
subpopulation in a population of normal cells, and the growth 
fraction is unity. Psoriasis is believed to have a unity growth 
fraction, yet the important question remains: Does normal skin 
have a significant Go population? If, in fact, only a small percent 
of normal basal cells are actively proliferating (i.e., there is a 
large Go subpopulation), they may have the same cell cycle as 
psoriatic cells. Such a finding would attach a portion of the 
psoriatic defect to those factors that determine how many and 
which cells are to proliferate rather than to those factors that 
determine how long the cell cycle is to last. Growth fraction 
studies on human skin must be attempted even though in 
animal cutaneous studies the growth fraction approximates 
unity. 
Rapid proliferation in psoriasis can be considered as a re-
sponse to an (presumed) inherited predisposition to an abnor-
mal biochemical sequence of events. It is apparent that unin-
volved psoriatic skin has an abnormally high proliferation re-
sponse to nonspecific and specific stimuli. Further research is 
required to identify which cells are stimulated in psoriasis, the 
biological .and biochemical parameters of this response, and the 
therapeutic means to prevent overproduction of cells and to 
restore epidermal cells to normal proliferation. 
The fundamental psoriatic defect is undoubtedly linked to 
how individual genetic makeup regulates cellular growth. The 
answer to this question is a pivotal matter in all of cell biology, 
since it pertains to an understanding of cancer as well as of 
psoriasis. 
Growth of cells is assumed to be modulated physiologically 
by factors that stimulate and inhibit growth. Those that regu-
late growth by inhibition are termed chalones. A chalone is 
defined as a tissue specific, species nonspecific substance that 
maintains epidermis in a normal state of balanced proliferation 
and differentiation. Two distinct chalones have been identified· 
one inhibits the G1 phase of the cell cycle, the other the G2 . l~ 
spite of serious efforts to isolate chalones from skin, only partial 
pmification has been accomplished. Nevertheless, the chalone 
concept, which is regulation by restraint, is fundamentally 
sound, and the isolation and purification of such a substance 
may come about with improved technology. . 
Several agents are capable of regulating growth by stimulat-
ing cell proliferation, such as somatomedin, platelet factor, 
epidermal growth factor (EGF) and fibroblast growth factor 
(FGF). Thus a growth factor could stimulate a genetically 
predisposed skin, or the skin could produce abnormal quantities 
of growth factor locally, causing continuous local stimulation of 
skin cell proliferation. 
Cell Differentiation 
During the morphologic differentiation process, the skin basal 
cell either continues proliferation and remains a stem cell or 
stops replication and begins specialization. During the period 
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of specialization, certain phases that take place in the normal 
cell do not occur in the psoriatic cell: the keratohyalin granules 
do not develop and remnants of nuclei in the stratum corneum 
do not disappear. These are 2 of the most p'rominent defects at 
the morphological level. It is not known whether defects in the 
maturation process are the primary events in the psoriatic 
lesion or secondary events following failure in the replicative 
process. The experimental approaches that are currently used 
in molecular genetics should be applied in studies of the defect 
in psoriasis: what are the genes that control chromosomal 
replication within the basal cell and how are these genes trans-
lated into the products of differentiation, viz., mature keratin 
and keratohyalin? 
Cell Surface Interactions 
There is an increasing body of evidence to show that specific 
alterations in the cell surface are closely associated with mitosis, 
early growth, and transformation. In skin, it appears that a new 
surface constituent must be synthesized to bring about the 
orderly transition of a replicative basal cell to a nonreplicative 
malpighian cell . Through use of electron microscopy to study 
the maturation of the cell surface, it was found that normal 
cells in the basal layer lacked a surface coat. As the cells moved 
toward the stratum corneum an increase in the amount of 
surface polysaccharide occurred. By applying these same tech-
niques to psoriatic skin , it was observed that the glycocalyx was 
either strikingly diminished or completely lacking. Following 
therapy with methotrexate the glycoprotein-rich layer reap-
peared. Scanning electron microscopy reveals the abnormal 
architecture of the cell surface of the psoriatic keratinocyte 
with its inv'aginations and villi. 
Changes in the cell surface can be detected by direct obser-
vation. In addition, there is a large body of biochemical evidence 
to indicate an abnormal surface reactivity. That the psoriatic 
cell responds differently to stimulation by prostaglandins and 
by catecholamines from the normal cell is now well established. 
. Recently, a striking specific increase in the activity of 3 mem-
brane-associated enzymes at the cell surface of psoriatic skin 
(aryl sulfatase A and B, and ,B-glucosidase) has been reported. 
Microcirculation and Angiogenesis 
A number of investigators have observed that dilated capil-
laries can be found at the advancing edge of a psoriatic lesion 
where epidermal hyperplasia has not yet begun. When the 
normal-appearing skin of psoriasis is observed by electron mi-
croscopy, endothelial cell gaps can be seen in the postcapillary 
venules in both the normal-appearing skin and, with a higher 
frequency, in the lesion. These gaps look like those produced 
by histamine and bradykinin. They may indicate a potential for 
increased leakage of the plasma constituents into the dermis. 
The lymphatics, too, are highly developed in both the psoriatic 
lesion and the normal-appearing skin. 
One of the physical signs of psoriasis in the Auspitz sign: the 
appearance of small bleeding points when the scales of psoriasis 
are removed. These minute bleeding points graphically illus-
trate the increased proliferation of. capillaries in lesions of 
psoriasis. There is now evidence that rapidly proliferating tis-
sues and capillaries constitute a highly integrated system. 
Growth of tumors, for example, does not occur without a 
concomitant increase in their blood supply. To promote capil-
lary growth, tumors synthesize and secrete a factor that stim-
ulates capillary endothelial cells. This substance, the tumor 
angiogenic factor (TAF), has been isolated from tumors and 
partially purified . An epidermal angiogenic factor, different 
fTom the tumor angiogenic factor, also appears to be present in 
the epidermis. 
Foreign Cell Invasion 
The role of infIltrating cells in the development of the pso-
riatic lesion is speculative. Reports indicate that there is some 
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deficiency in the number and/or function of T cells in patients 
with psoriasis. There is also some evidence that the delayed 
type of hypersensitivity is defective in people with psoriasis. On 
the other hand, most immunological studies, and there have 
been relatively few, have not yet clarified the role of the immune 
response in psoriasis. Lymphocytes are commonly found in 
psoriatic lesions and these are present in the mid-dermis and 
upper dermis around the papillary vessels. The role of these 
lymphocytes is unknown; it may be secondary, not primary, to 
the lesion. It is well known that "neutrophils" tend to migrate 
into the epidermis and accumulate in small pockets within the 
epidermis and horny layer. Presumably there are leukotaxic 
materials liberated by the epidermis that attract these cells. It 
is probable that this is a secondary and not a primary event in 
psoriasis. The increased number of mast cells in early psoriatic 
lesions suggests that these cells take part in developing the 
lesions. The influence of inflammatory cells in the development 
of psoriatic lesions is an important subject for further explora-
tion. 
Lesion-Free Skin 
Recent progress in studies of "normal-appearing" skin in 
patients with psoriasis may open new approaches to patho-
physiology of psoriasis, preventive therapy, and genetic coun-
seling. A body of information now exists which suggests that 
the normal-appearing skin in psoriatic patients is abnormal. It 
is known that a variety of physical stimuli cause lesions to 
appear in normal-appearing skin in some people with psoriasis, 
a condition called The Koebner Phenomenon. Various medi-
cations, including chloroquine, corticosteroids, practolol and 
lithium, precipitate or flare psoriasis by unknown mechanisms 
in predisposed individuals. The sudden onset of guttate pso-
riatic lesions, particularly in young people, has followed a 
streptococcal infection, presumably linking an infectious toxic 
product with a stimulatory site of psoriasis. Biological and 
biochemical differences, i.e., reactive hyperemia, cholesterol 
esterification, dermal capillary tortuosity, vascular response to 
histamine and tetracycline content have been reported in nor-
mal-appearing psoriatic skin and not in normal nonpsoriatic 
skin. It is not clear, however, whether these differences relate 
primarily to the cause of psoriasis or are secondary to extra-
neous factors. 
It has been shown that 48 hr after cellophone tape stripping, 
normal-appearing psoriatic skin has more DNA-synthesizing 
cells than normal, skin in nonpsoriasis volunteers. This finding 
is important because it provides a link between the abnormal 
psoriatic skin lesion, which also contains more DNA synthesiz-
ing cells than normal skin, and an abnormality of normal-
appearing skin in psoriasis. This work has been extended. A 6-
fold increase has been found in the number of DNA-synthesiz-
ing cells in normal-appearing psoriatic skin 48 hr after injecting 
a propranolol solution. A similar increase was not seen in the 
normal skin of subjects without psoriasis. 
Genetics 
The familial occurrence of psoriasis has made dermatologists 
aware of genetic influences in susceptibility to that disease. 
Heritability of psoriasis is consistent with a dominant mode of 
inheritance in which ultimate expression of disease is affected 
by modifying factors. Given this thesis, it is not unreasonable 
to postulate that a single major gene is primarily responsible 
for determining psoriasis susceptibility. Such a gene would 
interact with other modifying genes and with unknown envi-
ronmental factors to produce clinical disease in an individual. 
Identification and characterization of a "psoriasis-susceptibility 
gene" would be an important development. Persons susceptible 
to psoriasis might be identified before the onslaught of the 
disease; clinically significant subgroupings of disease could be 
made; perhaps even more about the pathogenesis of psoriasis 
might be revealed. ATecent 'step forward has been made in a 
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series of studies in several centers in which correlations were 
reported of the occurrence of psoriasis with genetic markers as 
determined by the major histo-compatibility (HLA) system. 
The combined data from these studies show that individuals 
possessing the B17 antigen have an approximately 5-fold greater 
likelihood to develop psoriasis vulgaris than randomly selected 
individuals. Although these locus antigens appear to provide 
markers for postulated neighboring disease susceptibility genes, 
preliminary studies of the nearby HLA-C and -D loci suggest 
that some of these alleles may provide even better markers of 
psoriasis susceptibility, particularly with the Cw7 and LD17 
antigens. Certain variants of psoriasis may be more strongly 
associated with one marker than with another; e.g., patients 
with the B17 antigen appear to have an early age of disease 
onset; those with the Bs16 antigen do not. 
Dermal-Epidermal Interaction 
The dermis is an essential participant in the maintenance of 
epidermal proliferation. Considerable research has been per-
formed on the biological and biochemical functions of dermis, 
mostly aimed at its supportive role in epidermal function. Little 
is known about the part the dermis might play in the primary 
etiology of the psoriatic lesion. 
DNA, RNA Metabolism 
The increased number of DNA synthesizing cells is one of 
the identified biochemical changes in the psoriatic plaque. 
Evidence has been obtained that the normal-appearing skin of 
the psoriasis sufferer, as well as tissue not usually affected with 
the disease (buccal mucosa), may also show increased rates of 
nucleic acid synthesis. These observations indicate a basic 
defect in the control of nucleic acid synthesis in psoriatic 
epithelial cells. We have little understanding of the pathways 
for synthesis of the purine and pyrimidine nucleotide precursors 
and their subsequent incorporation into DNA and RNA. We 
. may ask the question , "Do rapidly proliferating psoriatic skin 
epithelial cells use a de novo pathway for pyrimidine synthesis 
to the same extent as the normally proliferating epithelial cell?" 
The increased susceptibility of psoriatic cells to methotrexate 
suggests that they do not. 
During the process of normal keratinization of epithelial cells, 
DNA and RNA are completely hydrolyzed. In psoriasis this 
hydrolysis is incomplete, and parakeratotic nuclei are fre-
quently found in the stratum corneum. The presence of par-
akeratotic nuclei may be a consequence of a decreased transit 
time, or perhaps it may indicate a more basic defect in the 
regulation of nucleic acid degradation. 
Uric acid is the end product of purine catabolism in liver. In 
about 50% of subjects with psoriasis, increased levels of uric 
acid are found in the blood; in some, the increase does not 
appear to correlate with the extent of skin involvement. The 
increase in some subjects may be a reflection of an accelerated 
turnover of epithelial cells (secondary gout) or it may arise from 
a TIlore basic defect in the regulation of purine synthesis and 
catabolism (primary gout). In the one study on this important 
point, it was observed that the specific activity of 14C-glycine 
incorporated into uric acid excreted in the urine of psoriasis 
patients fell between that of patients with primary and second-
ary gout. 
Protein Metabolism 
The theoretical background and technical expertise that now 
exist regarding protein synthesis and its control during normal 
epidermal keratinzation stimulates investigation on protein ab-
errations in epidermal hyperplasias such as psoriasis. In the 
past 5 years, specific protein components of tonofUaments, 
sulfur-rich and sulfur-poor keratohyalin granules, and keratin 
fibers have been identified, characterized, and localized in nor-
mal epidermis, in situ. There is reason to · believe that hyper-
plasia involves abnormalities in each of these cellular structures, 
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and, in one case, the sulfur-poor keratohyalin granules are 
known to be absent in the active psoriatic lesion and to reappear 
early in remission of the disease. 
Carbohydrate Metabolism 
The initial impetus to research in carbohydrate metabolism 
in psoriasis arose from the finding of increased glycogen shown 
histochemically in psoriasis lesions. This greater amount of 
glycogen in the psoriasis lesion over that in normal and unin-
volved skin of the psoriatic was confirmed by biochemical 
analysis 10 years ago. Research into the enzymes that are 
involved in the metabolism of glucose and in the formation of 
glycogen has been extensive. 
In general there are greater amounts of enzymes for carbo-
hydrate metabolism in the psoriatic lesion than in the unin-
volved skin or normal skin. The major increase, however, occurs 
in the 2 enzymes that lead to ribose-5-phosphate. These are the 
enzymes of the "hexosmonophosphate shunt," called glucose-6-
phosphate dehydrogenase and 6-phosphogluconante dehydro-
genase. The activity of these enzymes in the psoriatic lesion is 
4 to 5 times that of the normal. It is thought that the increased 
activity is related to the increased epidermal proliferation, since 
these enzymes supply the ribose phosphate needed for nucleic 
acid synthesis. In addition, they account for the NADH neces-
sary for lipid metabolism, which, in turn, may also be critical in 
the maintenance of the psoriatic lesion. 
Studies on the formation and breakdown of glycogen in the 
psoriatic lesion have shown that the glycogen is made and 
broken down at the same rate as it is in normal skin; the 
difference is that the steady state level of glycogen is 4 to 5 
times higher than that in normal skin or in the uninvolved skin 
of the psoriatic. The function of this glycogen is unknown. It is 
not thought to contribute to energy metabolism since there is 
too little of it to sustain skin metabolism for more than 10 min 
or so. Although research on the function of the increased 
glycogen content should not be totally neglected, it does not 
seem to bear directly on increased proliferation and is in all 
probability only a secondary effect of increased proliferation. 
Lipid Metabolism 
That lipid metabolism increases in psoriatic lesions was 
shown 15 years ago. The ratio of cholesterol to cholesterol 
esters increases, too, in psoriatic lesions and scales. It is also 
quite apparent from more recent studies that essential fatty 
acids are necessary for normal keratinization and that a scaling 
dermatitis results from essential fatty acid deficiency. Scaling 
can be corrected by supplying the essential fatty acids. A drug 
that was used to treat hypercholesterolemia (MER-29) caused 
severe scaling. 
During keratinization, at the level of the granular layer, cell 
organelles disappear. It has been pointed out that almost all of 
the phospholipids and triglycerides within the cell are meta-
bolised, leaving cholesterol, cholesterol-esters and sphingolipids 
behind. These changes seem to be essential for normal keratin-
ization. Thus while abnormalities of lipid metabolism may 
result in abnormal keratinization, no specific changes have as 
yet been identified in psoriasis. 
Cyclic Nucleotides 
The cyclic nucleotides, cyclic AMP and cyclic GMP, are the 
intracellular so-called second messengers of hormones and neu-
rotransmitters that act at the cell surface. Ih cultured cells 
cyclic AMP can either slow or stimulate growth and, in some 
cells, can stimulate cell differentiation. Although it is not fully 
known at the present time, how growth of epidermal cells by 
cyclic GMP is regulated, it has been ascertained that in certain 
cell types increased cyclic GMP levels are associated with 
greater cellular proliferation. 
In psoriasis the abnormalities of the epidermal compartment 
are a major feature of the disease. Psoriatic epidermis shows 
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reduced morphological differentiation, increased proliferation, 
and an accumulation of epidermal glycogen. Cyclic nucleotide 
metabolism has been extensively studied in psoriatic epidermis 
with conflicting results. Cyclic AMP levels in lesions have been 
reported as decreased, normal, or increased, depending on the 
experimental approach. Cyclic GMP has been found elevated; 
the response of adenylate cyclase to beta catacholamine re-
duced. It appears that the steady-state cyclic AMP content of 
lesions is quite variable. In fact, the variable levels may indicate 
that shifts occur with changing cellular metabolism. Conse-
quently, research in this field has moved to investigation of 
those factors that regulate cyclic nucleotide formation and 
function in epidermis. 
In spite of uncertainty as to the exact levels of cyclic AMP 
metabolism in psoriatic leslou';, interest in this area is high 
because cyclic AMP is considered a good candidate for an 
essential modulator of epidermal proliferation, of differentiation 
and of glycogen metabolism in psoriasis. In vitro, cyclic AMP 
inhibits epidermal proliferation, possibly stimulates epidermal 
differentiation, and can reduce the glycogen content of psoriatic 
lesions. Since these 3 features are absent from normal epider-
mis, the local elevation of cyclic AMP in lesions of psoriasis 
may improve the lesions. Furthermore, certain of the growth 
factors (e.g., EGF or FGF) described earlier appear to act by 
altering the cellular levels of cyclic AMP. Thus learning more 
about cyclic AMP metabolism is essential to the understanding 
of how growth factors can alter cellular proliferation. 
Although there is information suggesting that cyclic nucleo-
tides may be regulators in cell proliferation, their role is yet to 
be specified. 
Prostaglandins 
Prostaglandins are a unique class of biologically active lipids 
that are found in most, if not all, living human tissues. Prosta-
glandin is a generic term for a variety of metabolites of arachi-
donic acid. Prostaglandins are involved in the regulation of a 
variety of physiological processes. Prostaglandin-like molecules, 
thromboxane, PGE2, HETE and PGh may participate in the 
pathophysiology of several abnormal states, for example, in-
,flammation, fever, cancer, periodontal disease, dysmenorrhea, 
and asthma. How prostaglandins act is not clear. However, the 
best known cellular mediators of prostaglandin action are cyclic 
AMP and cyclic GMP. Prostaglandins raise the cellular level of 
cyclic AMP (usually not cyclic GMP) in most tissues and have 
at least part of their action via this cyclic nucleotide mechanism. 
Prostaglandins are of interest in psoriasis for 2 major reasons: 
(1) as previously discussed, cyclic nucleotides are thought to be 
excellent candidates for regulator of proliferation, differentia-
tion, and glycogen metabolism in psoriatic lesions; (2) the 
psoriatic lesion is very inflamed and shows significant vasodi-
lation. Prostaglandins are known participants in the inflam-
matory response and in particular are dilators of the human 
cutaneous vasculature. Therefore, prostaglandins may regulate 
epidermal homeostasis on the one hand and, on the other, may 
participate in the pathophysiology of inflammation in the lesion 
in yet a different layer of the lesion. 
Prostaglandins are excellent candidates for regulators of 
cyclic nucleotide metabolism in skin because they do not cir-
culate but act as local hormones and are made and degraded 
locally. A local regulator of cellular metabolism must exist in 
psoriasis and other skin diseases because localized lesions are 
the rule and generalized disease the exception. Gene~alized 
disease derives from centrifugal spread and coalescence of in-
dividuallesions. If a blood borne mediator of cellular regulation 
were operating in psoriasis, total body psoriasis would be the 
rule, whereas, in fact, it is the exception. 
Mediators of Inflammation 
Inflammation in the clinical and pathological changes of 
psoriasis is a self-evident fact. Even in common chronic plaque 
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psoriasis, lesions exhibit erythema and warmth, indicative of 
increased blood flow. In psoriatic erythroderma and generalized 
pustular psoriasis, inflammation is the dominant clinical feature 
and is frequently accompanied by fever. Joint involvement, 
when present, is inflammatory and destructive. Microscopic 
examination of skin reveals neutrophil invasion and comple-
ment deposition in the involved epidermis. An effective nonste-
roidal anti-inflammatory agent would be of considerable ther-
apeutic value in psoriasis; none has yet been found . Important 
clues on effective drug suppression of psoriatic inflammation 
can be gained from systematic pharmacological studies of in-
flamed psoriatic skin. 
Little has been done to find and identify mediators of in-
flamed skin in psoriasis. 
Increased concentrations of prostaglandin E 2 (a vasodilator), 
the prostaglandin precursor arachidonic acid, and its leucotactic 
fatty acid metabolite (HETE) have been identified in psoriatic 
plaques. Emphasis has been placed on the possible cytokinetic 
actions of these agents; yet their ability to reproduce the 
cardinal signs of inflammation makes them suspect as signifi-
cant participants in psoriatic lesions. Esterases, including the 
kinin-forming enzyme kallikrein (present in neutrophil leuco-
cytes), plasmin (present in blood vessel walls), and C1 esterase 
(present in plasma), are potential sources of vasoactive peptides. 
Several studies have identified these complement components 
in the involved epidermis of psoriasis. Although histamine is 
characteristically associated with short-lived wheal and flare 
reactions, its ready availability in skin mast cells and the recent 
identification of subclasses of histamine receptors on human 
skin blood vessels suggest that it may be culpable. Considera-
tion must also be given to novel, as yet unidentified, vasoactive 
mediators. 
Polyamines 
The polyamines, putrescine, spermidine, and spermine, are 
enzymatically formed in tissues from the amino acid ornithirIe. 
Putrescine, spermidine, and spermine are apparently necessary 
for the successful replication of cells. Consequently, in most 
proliferating cells the content of polyamines is increased. Be-
cause of the critical role of polyamines in cell proliferation, their 
metabolism has been examined in detail in psoriasis. The blood 
level of polyamines is increased in psoriatic patients, as are the 
urinary levels. In psoriatic lesions versus uninvolved epidermis 
of psoriatics, the polyamine content is higher, as are the activ-
ities of the polyamine forming enzymes. In uninvolved epider-
mis of psoriatics, the epidermal polyamine content is greater 
than that in normal epidermis suggesting that there may be a 
widespread basic biochemical defect in the epidermis of pso-
riasis patients. Since the number of proliferative cells in unin-
volved epidermis is increased, the elevated polyamine content 
of uninvolved epidermis may be a biochemical reflection of 
increased proliferative activity. It appears that in uninvolved 
epidermis "some cells" are proliferative, whereas in involved 
epidermis "more cells" are proliferative. Perhaps a biochemical 
defect in proliferative activity is qualitatively similar and quan-
titatively different in involved and uninvolved epidermis. In 
any case, agents that inhibit polyamine biosynthesis also inhibit 
cell proliferation in cultured cells. That such inhibition can be 
overcome by adding polyamines beyond the experimentally 
induced blockade certairIly supports the concept that polya-
mines are essential regulators of growth. 
Proteases 
One of the most characteristic histological features of pso-
riasis is the accumulation of neutrophil leukocytes in the par-
akeratotic stratum corneum. It has been shown that psoriatic 
scale contains leukotactic substances that may be products of 
complement activation. Extracts of tissue and cells contain 
proteinases that are able to generate chemotactic peptides from 
complement. Several laboratories have demonstrated that pso-
Nov. 1979 
riatic tissue has an increased content of proteolytic enzymes. A 
proteinase has been purified from whole human skin and human 
epidermis that induces a dramatic accumulation of polymor-
phonuclear leukocytes when it is injected into mice. This pro-
teinase has a molecular weight of 28,000 daltons, is inhibited by 
diisopropyl fluorophosphate, alpha2-macroglobulin, and soy-
bean-trypsin-inhibitor. It requires the presence of the fifth 
component of complement to induce neutrophil leukocyte ac-
cumulation. It has been recently reported that plaque from 
psoriatics contains significantly more of this chemotactic pro-
teinase than does their uninvolved tissue. Furthermore, there 
is no elevation of chemotactic proteinase in the disease pityr-
iasis rubra pilaris. These data strongly suggest that proteolytic 
enzymes may playa role in the polymorphonuclear leukocyte 
accumulation found in psoriasis. 
Proteinases in psoriasis may also be directly associated with 
cellular proliferation. Treatment of non transformed fibroblastic 
cells with proteolytic enzymes alters growth rates. Cells may be 
stiInulated to divide with plasma or thrombin. Incubation of 
transformed or neoplastic cells with inhibitors of proteinases 
returns the growth rate to normal. These data suggest that 
under certain conditions proteolytic enzymes can influence the 
rate of cellular division. 
Immunology 
There are reports that the skin of normal individuals contains 
antibodies directed against the stratum corneum. Various im-
munologic techniques, including immune adherence, mixed 
hernabsorption, passive agglutination, and immunofluorescence 
were used to demonstrate the presence of these antibodies. 
Direct immunofluorescent studies demonstrated the deposition 
of "intercellular and diffuse" IgG staining in the stratum cor-
neum, which was interpreted as being in vivo deposits of IgG 
stratum corneum antibodies. As supporting evidence the follow-
ing facts were cited: complement fixation of stratum corneum 
in vivo has also been detected; rheumatoid factor has been 
demonstrated in psoriatic scales; eluates of psoriatic scales 
contain IgG, IgA, IgM, C3, and low titers of stratum corneum 
antibodies. 
The investigators "consider their findings in the light of the 
available knowledge of the histopathology of psoriasis." They 
alluded to the fact that aggregated IgG is capable of activating 
the complement sequence and that various activated comple-
ment components, i.e., the trimolecular complex of C567, are 
potent neutrophil chemotactic factors. They implied that this 
may be the mechanism for the transepidermal migration (exo-
cytosis) of polymorphonuclear leukocytes common in psoriatic 
lesions. The investigators resorted to a 4 compartment analysis 
to semiquantitate the fluorescent staining, for they discovered 
that the fluorescein conjugates gave nonspecific stratum cor-
Deum staining. Furthermore, they noted that several of their 42 
control patients also demonstrated similar, if not identical, 
psoriatic-like staining patterns. Similar observations have also 
been made by other investigators suggesting a "psoriatic stain-
ing pattern" that is not specific for psoriasis. 
Lack of proper controls has aroused concern over the validity 
of some of these data. The staining pattern in the stratum 
corneum is lamellar and it appears along lines of cleavage that 
previously existed between epidermal cells before they became 
compacted in the keratinization process. These areas may bind 
and absorb proteins. Vasodilation and increased blood supply 
characterize psoriatic lesions. On the legs the psoriatic lesion at 
times "frankly weeps" (Tulipans variant of psoriasis). It may 
be that all types of proteinacious serum components (negatively 
and/or positively charged) present in large quantities in these 
highly vascular lesions may nonspecifically absorb into the 
stratum corneum. 
It is difficult to postulate a pathogenic role for the stratum 
corneum antibody in psoriasis in light of these facts: (1) stratum 
corneum serum antibodies are present in a high percentage of 
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normal individuals; (2) current knowledge indicates the stratum 
corneum is not in direct contact with the systemic circulation; 
(3) the stratum corneum is functionally dead; (4) a "psoriatic 
staining" pattern has been seen in nonpsoriatic patients; and 
(5) these "false" staining patterns have also been noted in skin 
diseases characterized by a thickened stratum corneum and 
increased vascularization (lichen planus and neurodermatitis). 
Recent preliminary data suggest that ultraviolet light may be 
an immunosuppressant agent. It was demonstrated that periph-
eral lymphocytes of psoriasis following treatment with UV-B 
displayed a decreased resting DNA synthesis as determined by 
:lH-thymidine uptake. 
Animal Models 
Animal diseases, such as the leukemias and solid tumors, 
have facilitated the development of experimental animal model 
systems for study of the pathophysiology and chemotherapy of 
the same diseases in humans. The lack of a naturally occurring 
disease analogous to psoriasis in animals has resulted in exten-
sive efforts toward creating psoriasis-testing models in animals. 
Since the etiology of psoriasis is unknown, it has not been 
possible to induce this disease state in animals. 
A primary factor in the pathogenesis of psoriasis is epidermal 
hyperplasia. Various experimental approaches, such as ultravi-
olet light exposure, treatment with chemical irritants such as 
retinoic acid, Scotch tape stripping, and wound healing, have 
been attempted to induce epidermal hyperplasia in animals as 
a model system for psoriasis. Although these techniques do 
produce increased mitotic activity and DNA synthesis, in-
creased cell proliferation is usually a delayed response to epi-
dermal injury and of limited duration. Animal models of hyper-
plasia have been useful for screening the pharmacologic activity 
of chemotherapeutic agents; however the predictive value of 
these models awaits adequate correlation with drug testing in 
humans. 
The mouse vaginal mucosa has been used to evaluate both 
systemic and topical agents. This model appears to be a reliable 
system for detecting topically active antimitotic agents. Al-
though preliminary data show a correlation of antimitotic ac-
tivity in the vaginal screen with topical antimitotic activity in 
psoriasis, further comparative studies are needed to establish 
the predictive value of the test. Two models for psoriasiform 
disease are the rat deficient in essential fatty acids and the 
hairless mouse. These animals develop severe scaly lesions in 
the skin, chru·acterized by aconthosis of the epidermis, increased 
mitotic activity and DNA synthesis in the basal layer, and 
thickening of the stratum corneum. This chronic state of epi-
dermal hyperplasia certainly seems to bear more resemblance 
to that in psoriasis than acute induced hyperplasia in other 
models. Studies now in progress to evaluate the cell cycle 
kinetics of epidermal proliferation in these models may lead to 
the scheduling of topical or systemic chemotherapy, as has 
been done with the systemic use of MTX in psoriasis. 
The athymic "nude" mouse is another promising model for 
the study of psoriasis. Transplanted involved psoriatic epider-
mis onto nude mice has maintained its characteristic histology 
for the 2 to 3 months survival period. The direct transfer of 
psoriatic tissue to the nude mouse without further growth 
severely limits this system as an experimental model. However, 
the model does lend itself to study of various therapeutic agents 
that would not be suitable for study in humans. Further studies 
are needed to compru·e the cell kinetic parameters and biochem-
ical characteristics of this model and human psoriatics. 
Tissue Models 
Over the past 2 decades many laboratories have added to our 
basic knowledge of the growth patterns and characteristics of 
human skin epithelial cells in cell culture, explant culture, and 
organ culture and of the requirements to ~eep them alive. 
Although in vitro models offer an opportunity to test several 
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important hypotheses on the etiology of skin disease, they have 
been seldom applied directly to psoriasis. 
The small amount of tissue obtainable from a single subject 
poses a major problem in psoriasis. Although many microtech-
niques have been developed to analyze' small quantities of 
tissue, more cells than can be obtained from a single 3-mm 
punch biopsy are frequently required. Cell culture techniques 
provide quantities of cells. When skin is exposed to dilute 
solutions of trypsin, epithelial cells are released into the growth 
medium. If plated on an appropriate surface, skin epithelial 
cells will attach and proliferate. So far all ofthe factors required 
to serially cultivate adult human skin epithelial cells have not 
yet been determined. Even so, up to 90 generations of growth 
can be obtained from foreskin, and at least 3 serial passages 
from adult human skin. When grown as isolated epithelial cells, 
keratinocytes will produce stratified cultures, form cross-linked 
cellular envelopes, and synthesize keratin. 
When placed epidermal side up on a glass coverslip and 
attached to the glass with a clot of chick plasma and embryo 
extract, epithelial cells migrate from the explant and multiply 
to form a confluent sheet within 3 to 14 days. The epithelial 
cells are polygonal in shape and stratify to form a multilayered 
sheet with cells in all stages of differentiation. The lower-most 
layer (those attached to the glass) are smaller and resemble 
those cells found in the basal layer. In the upper layers cyto-
plasmic organelles are absent and the plasma membrane is 
thickened. Both normal and psoriatic epidermal cells can be 
grown in explant culture. 
This model is simple and reliable, does not require large 
amounts of tissue, and may be particularly useful in studies of 
the factors in tissue that influence migration and attachment of 
epithelial cells. 
Of the models available to study skin in vitro, organ culture 
most closely reproduces the rriajor events of differentiation in 
in vivo . Small samples of skin are required, and the integrity of 
the epidermis is maintained for approximately 14 days. When 
the stratum corneum is removed, a new stratum corneum forms. 
Of the in vitro models, only organ culture provides a way to 
consistently observe the synthesis of keratohyalin granules, a 
prominent and major defect in psoriasis. 
In a 1969 organ culture study the surprising observation was 
made that the hyperplasia characteristic of the disease disap-
peared within 3 days, the tissue reverted to a more normal 
appearance, and a new stratified squamous epithelium was 
formed. The dermal papilla, characteristically elongated in the 
disease, also reverted to normal size. 
STATUS OF CLINICAL RESEARCH 
Pathophysiology 
The lesion of psoriasis vulgaris represents the sum total of an 
increased number of cells, a rapid rate of cell reproductioh, and 
an excessive production of end product, stratum corneum. At 
the biochemical level most, if not all , enzymatic processes that 
have been studi.ed in the lesion have shown increased activity, 
thereby producmg an overall hyperplastic cutaneous lesion. It 
is important to know how this hyperplastic process is initiated 
and perpetuated. Dermal components, including the vascula-
ture and fi.broblasts, appear to participate in this generalized 
hyperplastIC response. Where does the primary defect in pso-
riasis reside? In the epidermal cells? In dermal cells? Else-
where? No one knows. Markers or biochemical alterations in 
other readily available tissues, such as in lymphocytes, should 
be looked for. 
Psoriasis must cause widespread psychic disturbances in 
those so affected. A few studies of psoriatics have indicated a 
significant impact on the physical, emotional, and sexual aspects 
of their lives. Stresses produced by their disease and/or other 
unusual stresses may contribute to psoriatic flares. 
Clinicians have for years recognized that psoriasis occurs in 
many different forms. There is some question as to whether 
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some of the severe forms are actually related to ordinary 
psoriasis: pustular psoriasis, for instance, which, in its severe 
form, can be generalized and fatal, and Reiter's disease with its 
psoriasis-like skin lesions. The observation that psoriasis vul-
garis can occasionally be transformed into pustular psoriasis by 
the clinical use of systemic steroids remains unexplained. 
Although psoriasis primarily affects the skin, it has been 
suggested that other organ systems might be affected also. 
Synovium is the only tissue besides skin known to be clinically 
involved in psoriatic patients. Resulting psoriatic arthritis can 
be severely disabling. Many retrospective and prospective stud-
ies of the liver in psoriasis resulted from the use of antimetab-
olites for treatment of psoriasis. Initially the changes in liver 
pathology (fatty liver, inflammatory changes, cellular necrosis, 
fibrosis, and cirrhosis) were thought to be due to the drugs. 
Prospective studies subsequently showed that many patients 
never treated with antimetabolites suffered the same changes. 
The liver changes were not correlated with the severity of 
psoriasis; they were often due to nutritional deficiencies and/or 
alcohol consumption. Because treatment with methotrexate 
had become suspect, large numbers of psoriatics have had liver 
biopsies in the past 10 years. No evidence turned up to link 
psoriasis per se with liver disease. 
An increased incidence of thromboembolic phenomena was 
noted in one retrospective study of psoriatics. Three hundred 
patients with psoriasis treated with mycophenolic acid and 2000 
patients treated with PUV A showed no increase in incidence of 
thromb.oembolism. On the other hand, azaribine was withdrawn 
from the market because of a high incidence (3-10%) of throm-
boembolism in the drug-treated patients. The drug, not pso-
riasis, seemed to be the specific cause of the vascular problems. 
Several attempts have been made to correlate diabetes and 
psoriasis. However, at the present time such a correlation is yet 
to be established. Lipid abnormalities have been investigated 
by many groups. Type-IV hyperlipidemia is frequent in nondi-
abetic psoriatics. Psoriatic women over 30 and men under 30 
show significantly high cholesterol levels. Triglycerides are also 
significantly elevated in certain age groups of psoriatics. Uric 
acid metabolism is increased and patients with active psoriasis 
frequently have high uric acid levels. Just what the significance 
of these metabolic changes is has not been determined. 
Topical Therapy 
Topical therapy has been the mainstay in treatment for 
psoriasis with less than satisfactory results. There is nothing 
new about the drawbacks to the use of topical agents: unpleas-
ant aroma, staining, stinging, and burning the large areas of the 
body over which they must be applied, the grease that clings to 
clothes and interferes with activities of the patient. 
Uncertainty about percutaneous absorption presents a seri-
ous medical problem. It is almost impossible to estimate how 
much absorption will take place when materials are applied to 
disparate regions of the body over areas differing in size and to 
lesions in which the horny layer, which is the primary barrier 
to absorption, is in various stages of degeneration. Agents with 
a significant degree of toxicity that substantially penetrate the 
skin must be used warily in generalized topical therapy. 
The most effective locally applied drugs in the management 
of psoriasis are the glucocorticosteroids although they are less 
than curative. The harmful side effects are minor; consequently 
the benefit-to-risk ratio is satisfactory. The development of 
more potent topical steroids would probably increase side ef-
fects both locally and systemically. As mentioned previously, 
we have probably reached the optimum in balancing strength 
of topical glucocorticosteroids with local side effects. Topical 
steroids are extremely expensive for the average psoriatic pa-
tient, particularly if the disease is extensive. 
Crude coal tar has a· long history and wide acceptance in the 
treatment of many skin disorders. It is a by-product of the 
distillation of coal and is a heterogenous mixture of 10,000 
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different compounds, of which only about 600 have been chem-
ically identified. Despite its antiquity, the mechanisms by which 
tar accomplishes its therapeutic effects are still unknown. It is 
recognized that it is antipuritic, antibacterial, keratoplastic, and 
photosensitizing. Recent studies suggest that the antipsoriatic 
activity of various tars seems to parallel their phototoxic poten-
tialities. 
As a classic remedy in dermatology, tar has been compounded 
into lotions, shampoos, bath oils, and ointments. The numerous 
attempts to reduce its troublesome odor and staining have 
always ended in lowered efficacy. Tar gels, recently introduced, 
are emulsion colloids of tar in an emollient vehicle. These 
unique tar gels appear to deliver the beneficial elements of 
crude coal tar in a form both convenient to apply and cosmet-
ically acceptable. 
Perhaps tar's greatest usefulness has been in the treatment 
of psoriasis. Tar combined with ultraviolet light, in a treatment 
called the Goeckerman Regimen, can clear extensive psoriasis 
that often remains in long remission. Although tar alone is 
effective in treating psoriasis, the addition of ultraviolet light 
has a synergistic effect. In comparative studies of tar gel and 
crude coal tar in petrolatum in the Goeckerman regimen, the 
crude coal tar tended to produce a somewhat quicker therapeu-
tic response than the tar gels and may be a superior treatment 
for most patients. Other studies suggest that UVB in combi-
nation only with emollients may be equally effective. 
For many years the treatment was entirely empirical for 
there were no clues to the therapeutic mechanisms of the 
Goeckerman regimen. Recently, it was shown that the thera-
peutic benefits of coal tar to patients with psoriasis may be 
closely related to its ability to cross-link with DNA, thus 
affecting DNA synthesis. 
Despite its heterogenous nature, allergic contact dermatitis 
to crude coal tar is uncommon. Nor does crude coal tar produce 
systemic toxicity. A review of world research on tar products 
through 1966, identified only 13 cases in which topical tar or 
other tar preparations were implicated in the development of 
skin cancers in the area of application. In most of these, the 
cutaneous malignancy developed in the genital and surrounding 
skin areas after prolonged self-medication to the sites. 
There is some preliminary evidence to suggest that psoriatics 
are less likely to develop skin cancer than nonpsoriatics. This 
proposition should be put to more sound epidemiologic study. 
The development of chemotherapy for psoriasis has been 
strongly influenced by advances in systemic anti-neoplastic 
chemotherapy. A landmark observation in 1951 that systemic 
aminopterin (a folic acid antagonist) leads to the clearing of 
psoriatic lesions came shortly after the same drug was applied 
to produce remissions in childhood leukemia. Subsequent intro-
ductions of new drugs in cancer chemotherapy have provided 
a basis for studies by dermatologists of both systemic and 
topical forms of chemotherapy for psoriasis. At no time, how-
ever, have the 2 fields been in closer association than they are 
today. Ongoing studies by the pharmaceutical industry and 
independent laboratories have recently been augmented by a 
collaborative program (see below) to evaluate selected topical 
drugs for psoriasis. 
The concept of psoriasis as a hyperproliferative but benign 
disease suggested the rationale for therapy: drugs that would 
selectively affect rapidly proliferating cells. Methotrexate was 
found to inhibit DNA synthesis, block mitotic activity, and 
produce cell destruction in psoriatic skin after both systemic 
and intralesional administration. Unfortunately, despite the 
beneficial effectiveness of methotrexate systemically, it was 
useless topically. All cytotoxic, chemotherapeutic drugs admin-
istered systemically are likely to affect other organs of the body 
as well as the skin. Therefore, it would be quite useful to 
develop the means to enhance delivery of the drug to specific 
lesions and minimize systemic side effects. 
A number of empirical studies have shown that the benefit-
to-risk ratio is improved when dermatological medications are 
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applied topically rather than systemically. A prime example is 
the topical application of corticosteroid, which has cleared 
various skin diseases without the side effects associated with 
chronic systemic administration. Research should be encour-
aged to make topical application of cytotoxic agents more 
effective. 
Once a popular remedy in dermatology, ammoniated mercury 
is now infrequently used in the treatment of psoriasis because 
of its potential nephrotoxicity. 
Salicylic acid is a well-known keratolytic agent and is useful 
when combined with other agents in the treatment of psoriasis. 
In a 2-5% concentration it can be combined with crude coal tar 
to help resolve heavy plaques. Extensive body application of 
higher concentrations should be avoided or systemic toxicity 
may result. Salicyclic acid is presently added to the tar sham-
poos used extensively in the treatment of psoriasis. Recently a 
keratolytic gel containing propylene glycol and salicylic acid 
has proven effective in removing the thickened stratum cor-
neum in psoriasis. This preparation is also helpful when used in 
combination with the tar gels and topical corticosteroids. 
Anthralin or dithranol is an antipsoriatic drug of long stand-
ing and still has a place in the treatment of psoriasis. It is 
structurally similar to acridine, which is known to complex with 
DNA. The Ingram technique, in which anthralin paste, a coal 
tar bath, and ultraviolet irradiation are used, is well known. 
The mean treatment time for clearing psoriasis by this method 
is 20 days and the remission times appear to be shorter than 
those following the Goeckerman regimen. Although anthralin 
is effective, it is difficult to get patients to use it because it 
stains and is a primary irritant. 
Retinoic acid (vitamin A acid) cream has been tried in 
psoriasis with equivocal results. Vitamin A acid was used on 26 
patients, 24 of whom were somewhat improved. The granular 
layer reformed and a normal statum corneum was reconstituted 
after 2 weeks of treatment. However, 0.1% retinoic acid cream 
does not provide sufficient improvement to warrant its use in 
psoriasis. 
Systemic Therapy 
There can be little doubt that an effective drug taken inter-
nally is much simpler and more satisfactory to the patient and 
to the physician. 
Since kinetic cell studies have shown that part of the patho-
genesis of psoriasis involves rapid turnover of epidermal celis, 
it was reasonable to turn to antimitotic agents for treatment. 
These drugs limit the synthesis of DNA in epidermal cells by 
interfering with various enzyme cellular systems. This results 
in a slower till'nover time of epidermis and consequent clearing 
of skin. In addition, certain side effects are possible: hematolog-
ical suppression, liver abnormalities, gastrointestinal irritation 
and bleeding, and potential teratogenic and mutogenic changes. 
Methotrexate (MTX) is the oldest and only cytotoxic agent 
approved by the FDA for use in psoriasis. The drug is highly 
effective in the control of moderate to severe psoriasis. Indica-
tions, contraindications, and guidelines for the clinical use of 
MTX, laboratory studies on it, liver biopsies following its use, 
and its potential problems have been published. Studies have 
shown that MTX is hepatotoxic in certain dosage schedules. 
Pretreatment and followup liver biopsies are necessary to pre-
vent development of serious liver damage. Patients must be 
treated with the lowest possible doses of MTX; concomitant 
therapy should be used to reduce the dosage whenever possible. 
It should be administered only by or under the supervision of 
a physician experienced in antimetabolite therapy. 
Hydroxyurea has been used safely but not too effectively to 
treat psoriasis. Major side effects are bone marrow suppression 
and megaloblastic anemia. 
Triacetylayauridine, which had extensive clinical trials and 
was finally approved by the FDA in 1976, was withdrawn from 
the market soon afterwards because of the incidence of throm-
boembolism noted in clinicaI use. 
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Mycophenolic acid has been tested but not approved by the 
FDA. This drug, an inhibitor of purine synthesis, has proved 
effective in carefully controlled clinical trials. However, long-
term side effects have included hematologic abnormalities, viral 
infections, urinary tract infections, diarrhea, and carcinoma. 
Certain analogs of retinoid A, known as retinoids, influence 
the growth and differentiation of keratinizing tissues. Aromatic 
retinoids have been used orally in the treatment of psoriasis in 
Europe since 1972. Within 4 to 8 weeks 50 to 80% of patients 
are approximately 75% cleared. Side effects from this therapy 
are: cheilitis, xerosis, alopecia, dry mouth, and elevated serum 
transaminase levels. In unpublished reports from Germany, 
retinoid has been effective in certain cases of exfoliative eryth-
roderma that were otherwise unresponsive to therapy. Recently 
it was shown that retinoids and PUV A can be used together. 
By combining retinoids with PUV A the number of PUV A 
treatments required to clear the skin can be reduced by one-
half. 
The mechanism by which retinoid acts is unknown. However, 
it has been shown by electron microscopy that increased 
amounts of mucopolysaccharidelike material are extruded from 
epidermal cells irito the extracellular space. It is also known 
that retinoids inhibit ornithine decarboxylase in experimental 
skin cancer. Since this enzyme is responsible for polyamine 
formation, perhaps retinoid is an inhibiting factor in the in-
creased polyamine formation characteristic of psoriasis. 
Steroid compounds have been used for many years in the 
treatment of psoriasis. Although they have produced a benefi-
cial effect in patients, they have also produced the usual unto-
ward side effects typical of systemically administered steroids. 
Of major concern to dermatologists has been the resistance that 
psoriatic lesions gradually develop to steroids. Higher and 
higher doses are required and more and more toxic side effects 
develop. Upon discontinuance, psoriasis rebounds. While using 
systemic steroids, occasional patients have developed a pustular 
form of psoriasis more difficult to treat. There still remain 
instances when systemic steroids are the only drug of benefit to 
psoriatic patients, particularly those with psoriatic arthritis and 
those with such extensive forms of psoriasis that they are not 
responsive to other systemic chemotherapeutic drugs or pho-
totherapy. Alternate-day therapy to minimize side effects is 
recommended in the care of these few patients. 
It is well known that most patients with psoriasis are better 
when exposed to sunshine. This effect is due to ultraviolet light. 
The ultraviolet light spectrum (UVL) is divided into the UVC 
region (200-280 nm) , the UVB region (280-315 nm) and the 
UV A region (315-400 nm) . UVC is not of consequence in the 
treatment of psoriasis. The mechanism by which UVL alone 
converts a hyperproliferative psoriatic epidermis into normal 
skin is a mystery. UVL irradiation alone causes only a transient 
decrease in epidermal DNA synthesis. It has been demonstrated 
that UVL-damaged skin has increased prostaglandin synthesis 
that might in some way be related to UVL's beneficial effects 
in psoriasis. In the presence of coal tar this biosynthesis of 
prostaglandins increases even further. In studies of Woronoffs 
ring (the fU'st areas to appear around many clearing plaques of 
psoriasis) it was found that UVL and coal tar therapy release 
an inhibitor of PGE, synthesis. 
Whether tar and UVL are synergistic has been a matter for 
controversy in the past. Studies now clearly show that in the 
treatment of psoriasis they are indeed synergistic. Controversy 
continues over the recent demonstration that on normal skin 
tar induced phototoxicity occurs only in the presence ofuv A 
in amounts not obtainable with light sources conventionally 
used in the Goeckerman regimen. Marisco et al, however, have 
clearly demonstrated that UVB is the effective portion of the 
UVL spectrum in the conventional Goeckerman regimen. Al-
though the therapeutic role of UV A by itself or in the Goeck-
erman regimen has yet to be fully demonstrated, it now appears 
that with some tar sources this combination also has a signifi-
cant beneficial effect in psoriasis. 
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The Goeckerman therapy has undergone a number of modi-
fications in the hands of different physicians. Despite these 
variations, this method has stood the test of time as a safe and 
effective form of therapy, especially for extensive psoriasis. To 
be effective, the regimen must be followed for from 2 to 4 weeks, 
after which long remissions can be expected. The success rate 
and recognized safety makes this treatment a preferred form of 
therapy for psoriasis. There have been no reports that tar and 
UVL treatment has led to an increased amount of skin cancer 
or has caused unacceptable cosmetic results. 
When psoriasis becomes very extensive or when complica-
tions develop, hospitalization is necessary. It is helpful to have 
a special dermatological section in the hospital with specialty 
nurses. 
The Goeckerman regimen and its variations have been a 
standard inpatient treatment for psoriasis for more than 50 
years. It has been extended to include topical corticosteroids, 
tar baths, and anthralin therapy. The average hospitalization 
period is 2 to 3 weeks, followed by clinical improvement and 
remission in almost all patients for 6 to 8 months (some remis-
sions last years). 
Hospitalization also may be necessary to treat psoriatic ar-
thritis, to do a liver biopsy in preparation for methotrexate 
therapy, or ' to perform other tests in preparation for systemic 
therapy. Complications arising from therapy for psoriasis may 
also result in hospitalization. 
Photochemotherapy 
Photochemotherapy is new in the treatment of psoriasis and 
is still in the investigational stage. The idea for its application 
came from ' basic research with psoralen and its photo toxic 
reaction on psoriatic plaques exposed to UVL. The inhibition 
of S phase of the cell cycle by psoralens and black light led to 
the thought that the abnormal proliferation of epidermal cells 
in psoriasis might be so inhibited. Clinical trials in which UV A 
and psoralens were applied topically were encouraging. Recent 
studies and clinical trials have validated and extended the use 
of topical psoralens and UV A. In 1974 it was reported that 21 
psoriatics were completely cleared after topically applied high 
intensity artificial UV A and orally administered psoralen. 
Studies in the United States and foreign countries have 
confirmed the short-term effectiveness of this form of therapy 
with only minimal side effects. Twenty-six centers in the USA 
are involved in a clinical cooperative study in which more than 
2,000 psoriatic patients have been treated with photochemo-
therapy. Eighty-five percent of the psoriatic patients cleared in 
an average of 20 treatments. The major side effects were ery-
thema, nausea, and pruritus. The studies revealed that most 
patients require long-term maintenance therapy with photo-
chemotherapy either once a week or once every two weeks. 
Standards have been set for the total amount of UVL exposure 
(time and intensity) required to clear the lesions and the daily 
dosages of psoraJen and UV A in these studies. 
Photochemotherapy is primarily an outpatient therapy. It 
obviates the use of topical steroids, tars, anthralin and other 
agents that often are unacceptable to patients. It also avoids 
the use of methotrexate and other cytotoxic drugs that require 
constant monitoring for hematologic, hepatic, and other poten-
tial long-term side effects. Furthermore, when a rebound of 
psoriasis occurs after methotrexate or topical steroid therapy is 
discontinued, photochemotherapy on an outpatient basis can 
be substituted for the expensive hospitalization formerly re-
quired. 
NEEDS FOR ADDITIONAL BASIC RESEARCH 
Biological Aspects 
Study of the basic pathological lesion. Research is needed to 
determine the common pathways of psoriatic lesions in order 
to identify ways to interfere with the earliest common events. 
Cell proliferation and its controls. Research is needed to 
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determine whether all cells in psoriatics proliferate somewhat 
rapidly or whether only a few cells proliferate at a very high 
rate. Investigations aimed at purifying epidermal chalones and 
growth factors should be pursued. Basic studies on the regula-
tion of proliferation by these chalones and growth factors should 
give rise to new therapeutic approaches. 
Characteristics of the cell surface. Developments in biologi-
cal technology, including new cell culture techniques and sen-
sitive radioactive probes, now make it possible to analyze cell 
surface architecture. These methods should be applied to the 
study of the dividing and differentiating cell layers of the 
epidermis to determine if a basic defect in the cell surface of 
epidermal cells contributes to hyperproliferation. 
Cutaneous microcirculation. A comprehensive study of the 
vascular changes occurring at all stages of the development of 
psoriatic lesions is essential. Some relevant questions are: Do 
gaps in endothelial cells reflect a basic genetic defect in the 
structure or do they indicate a hyperactive response to a bio-
chemical cue originating in the epidermis? Does the rapidly 
proliferating psoriatic epithelial cell synthesize and secrete an 
angiogenic factor similar to a tumor cell? If so, is increased 
blood vessel proliferation in psoriasis stimulated by such an 
angiogenic factor? 
Study of uninvolved psoriatic skin. Studies on epidermal 
proliferation may indicate a difference between apparently nor-
mal psoriatic skin and the skin of normal persons. If this is so, 
there would be certain practical implications. 
1. This difference could be used to aid in the diagnosis of 
psoriasis, at present difficult, particularly in the case of unusual 
variants, such as "hand-foot psoriasis." 
2. A proliferative difference might be exploited as a test for 
the "psoriatic state." Such a test for latent psoriasis could aid 
genetic counseling. 
3. Methods might be developed to modify these proliferative 
differences thereby preventing skin lesions from ever develop-
ing. 
Genetic research. Several mechanisms have been postulated 
to explain the relationship of HLA antigen linkages to psoriasis. 
There are no substantive data to prove any ofthese hypotheses. 
Whichever mechanism proves to be ultimately correct, it is 
likely that om increased understanding of the association of 
HLA genes with psoriasis genes will contribute to om under-
standing of the disease process. Genetic research of psoriasis 
deserves support. 
Biochemical Aspects 
DNA and RNA metabolism. Regulation of nucleic acid me-
tabolism in psoriasis is an unexplored area. Studies are needed 
of the mechanism by which the psoriatic epithelial cell regulates 
DNA and RNA synthesis as well as the more general problem 
of whether normal and psoriatic patients differ in their systemic 
metabolism of nucleic acids. 
Protein metabolism. The absence of keratohyalin in the 
active lesion is a featme of psoriasis. Keratohyalin is character-
ized by the presence of a histidine-rich protein. Studies should 
be supported to determine whether the absence of keratohyalin 
is the result of a metabolic failme to synthesize the histidine~ 
rich protein and, if so, whether this failure arises from an 
inability to synthesize the basic protein monomer or from an 
inability to polymerize the monomers into a protein chain once 
they are formed. 
Carbohydrate and lipid metabolism. Electron microscope 
studies have shown that the smface of psoriatic cells differs 
from the surface of normal cells. Presumably these structmal 
differences relate to distmbances in glycoprotein metabolism. 
This area of cell surface chemistry is in its infancy, and it has 
not been studied at all in psoriasis. Basic studies should be 
supported to determine where the enzymes that attach the 
sugars onto protruding surface proteins are located and exactly 
how the type and arrangement of glycoproteins on normal and 
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psoriatic epidermal cell surfaces compares with those on other 
tissue cells. 
Phospholipase, an enzyme that liberates fatty acids from 
phospholipids, is extremely active in the psoriatic cell mem-
brane. From the fatty acids, large quantities of prostaglandin 
precmsors are released; products of the cyclo-oxygenase are not 
increased. The fate of the precursors deserves further study. 
Also, inhibitors of lipid synthesis must be evaluated in psoriasis. 
The study of the effect of lipid inhibitors that act at various 
stages of lipid metabolism has been neglected. 
Regulators of cell metabolism. Cyclic nucleotides are known 
to regulate cell proliferation and differentiation in vitro. Pros-
taglandins are locally-formed and degraded hormone-like 
agents that regulate the cyclic nucleotide content of skin cells. 
An a bnormality of cyclic nucleotide metabolism may contribute 
to the disease process, and studies directed toward identifyi ng 
those factors that control the cyclic nucleotide content of var-
ious skin cells are important. They may uncover the functional 
role of cyclic nucleotides within these cells. We must also 
determine whether other derivatives and precursors regulate 
cyclic nucleotide metabolism in vivo. Polyamines can regulate 
cell proliferation in vitro and polyamine formation in turn can 
be regulated by cyclic nucleotides. Thus, the modulation of 
polyamine production may be integral in psoriasis and should 
be studied. 
Mediators of inflammation. There is a need for direct study 
of the mediators of inflammation. Inflammatory exudate may 
be recovered in vivo from evolving and regressing inflamed 
psoriatic lesions and analyzed for chemical and biological activ-
ity. Substances with activity that do not fall into known main 
classes of media tors should be characterized. 
In order to correlate levels of mediator activity and levels of 
inflammation, it will be necessary to devise exact measures of 
vascular changes in psoriatic skin. Quantitative measurements 
of blood flow rate and distribution of blood flow must be 
determined in superficial cutaneous vessels. 
If studies show that lesions can be produced by injecting 
specific mediators of inflammation into psoriatic skin that looks 
normal, then it should be possible to develop rational drug 
therapy to block the action of these mediators. 
Proteases. It would be useful to investigate the action of 
proteolytic enzymes and polymorphonuclear leukocytes in cell 
division. By deciphering the role of proteases and polymorpho-
nuclear leukocytes in psoriasis, the role of proteolytic enzymes 
in other disease states may be disclosed as well. If proteases are 
implicated in the pathophysiology of psoriasis, protease inhib-
itors could become a new class of therapeutic agents. 
Immunological Aspects 
Although there is evidence that photochemotherapy, a new 
widely used treatment in psoriasis, may have an immunosup-
pressant effect, there is no substantial evidence to suggest that 
immunological mechanisms are functional in the pathogenesis 
of psoriatic lesions. It is essential, however, that studies on 
immunological mechanisms in psoriasis be pursued. 
Development of Laboratory Study Models 
Animal models of psoriasis. A suitable animal model for 
psoriasis research is not available. The strict regulations gov-
erning medical research in humans make in vivo studies, in 
most cases, impracticable. A major effort needs to be directed 
toward development of adequate animal models. 
Tissue culture models of psoriasis. Tissue and organ culture 
techniques are now at the stage where several fundamental 
aspects relating to psoriasis can be studied. These include. (1) 
rate of growth and factors regulating growth in cells isolated 
from involved and uninvolved psoriatic skin, (2) the karyotype 
of the psoriatic skin epithelial cell , and (3) the apparent greater 
lability of psoriatic cells in culture. 
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NEEDS FOR ADDITIONAL CLINICAL RESEARCH 
Topical Therapy 
Anti-inflammatory agents. Studies of anti-inflammatory 
agents should be encouraged to determine the most effective 
scheduling for topical steroid application to maximize the ther-
apeutic effect and minimize tachyphylaxis and side effects. 
There is an urgent need to develop anti-inflammatory agents 
that do not produce the side effects of corticosteroids, and to 
develop more efficient drug vehicles to transmit active drugs 
from the surface of the skin to the site of disease. 
Coal tar mixtures. Although coal tars have been used for 
over 50 years in the treatment of psoriasis, and are apparently 
safe, the active ingredients in the crude mixture have yet to be 
identified, and there is no documentation of the risks associated 
with their long-term topical use. Research should be supported 
to isolate the active ingredients of crude coal tar mixtures so 
that more effective compounds can be developed. Epidemiolog-
ical studies should be initiated on the safety of long-term coal 
tar therapy with and without ultraviolet light. 
Topical cytotoxic chemotherapy. Topical chemotherapy with 
nitrogen mustard, thiotepa, and newer chemotherapeutic 
agents such as CCNU have been applied in the treatment of 
psoriasis. However, all of these agents have been associated 
with adverse reactions that limit their extensive use. Hundreds 
of cytotoxic agents are on the shelves of pharmaceutical com-
panies and the National Cancer Institute. Most of these agents 
have been tested in various animal malignancies. Some studies 
are now underway to test selected chemotherapeutic agents in 
minute quantities directly on volunteer psoriatic patients. 
These stl!dies deserve continued support and should be ex-
tended in an effort to speed up the identification of potentially 
useful drugs. 
Other drugs. Less irritating and non-staining anthralin prep-
arations should be developed. The use of vitamin A acid and 
salicylic acid should be investigated further. 
Physiological regulators. As we learn more about the under-
lying physiological disturbances in psoriasis, it will become 
possible to take a more scientific approach to therapy. For 
instance, prostaglandins are lipids and should penetrate the 
stratum corneum barrier easily. Although some prostaglandin-
like molecules or precursors are present in excess in psoriatic 
lesions, others when applied to the skin may be beneficial. 
Topical application of prostaglandin analogues, adenosine an-
alogues, and inhibitors of cyclic AMP breakdown should be 
studied. Compounds that inhibit the formation of arachidonic 
acid and HETE should be tested. 
Agents, such as a1pha-methylornithine and methylglyoxal 
bisguanylhydrazine, that are blockers of polyamine formation 
should be studied to see if they reduce cell proliferation in 
psoriasis. 
Systemic Therapy 
Systemic cytotoxic agents. There are no ideal drugs that can 
be administered systemically for the treatment of extensive 
psoriasis. The difficulty and expense of developing such agents 
may account for the limited activity of pharmaceutical compa-
nies in this area. Cytotoxic agents developed by NIH or other 
agencies for cancer chemotherapy should be evaluated for their 
potential usefulness as effective and safe chemotherapeutic 
agents in widespread psoriasis. Methotrexate, a systemic cyto-
toxic drug developed for cancer chemotherapy, is effective in 
widespread psoriasis. Surveillance of patients undergoing meth-
otrexate therapy should be continued to uncover unusual or 
unexpected long-term toxicity. Long-term followup for potential 
ad verse effects must accompany the application of any systemic 
agent. 
Systemically-administered retinoids. How systemically-ad-
ministered retinoids act is unknown; however, retinoids have 
been used orally in the treatment of psoriasis in Europe since 
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1972. Within 4 to 8 weeks after treatment is initiated, 50-80% 
of the patients are approximately 75% cleared of lesions. It is 
known that retinoids inhibit ornithine decarboxylase in exper-
imental skin cancer. Since this enzyme is responsible for poly-
amine formation, perhaps retinoids inhibit the increase in pol-
yamine formation characteristic of psoriasis. Studies to clarify 
the action of retinoids and to determine their efficacy as sys-
temic therapeutic agents should be supported in this country. 
Dialysis: Recent observations suggest that circulating factors 
may participate in the pathophysiology of erythrodermic pso-
riasis. Dialysis is evidently therapeutically effective in the man-
agement of this disease. Although dialysis is a drastic therapeu-
tic approach, support for studies in this area might lead to the 
disclosure and isolation of the circulating factors involved in 
the genesis of psoriatic lesions. 
Tar and UV Therapies 
High intensity UV A radiation is used alone in Europe to treat 
psoriasis. Studies should be made on modifications and combi-
nations of our present methods by using both ultraviolet A and 
ultraviolet B radiation with and without tar. Frequency and 
length of exposure should be studied to develop the most 
efficient and safe therapy protocols. 
Prospective studies should be initiated on the possibility of 
carcinogenesis from ultraviolet light therapy with and without 
tar. 
Photochemotherapy 
One of the most promising new therapies for psoriasis com-
bines a systemically-administered drug, psoralen, with high 
intensity l,Iltraviolet A radiation. Psoralen is chemically modi-
fied in the skin by the absorbed ultraviolet light and becomes 
a cytotoxic agent. The PUV A effect is localized to the skin 
(eyes may be protected) and has the advantages of systemic 
cytotoxic drug therapy without the disadvantages. 
Other similarly targeted agents should be sought for use in 
diseases of skin cells. Research with psoralens and other non-
toxic systemic agents which can be activated by ultraviolet or 
other wavelengths must be continued. 
Because PUV A treatment has been so successful and is 
highly acceptable to patients, there has been a great deal of 
pressure to rashly approve this therapy before laboratory stud-
ies are completed. Many experimental model systems warn of 
potential danger with photochemotherapy. In view of possible 
long-term side effects, careful monitoring should be continued. 
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